Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jan 10;1(1):CD011659.
doi: 10.1002/14651858.CD011659.pub2.

Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis

Affiliations
Meta-Analysis

Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis

Daniela Gattini et al. Cochrane Database Syst Rev. .

Abstract

Background: Portal hypertension commonly accompanies advanced liver disease and often gives rise to life-threatening complications, including bleeding (haemorrhage) from oesophageal and gastrointestinal varices. Variceal bleeding commonly occurs in children with chronic liver disease or portal vein obstruction. Prevention is therefore important. Primary prophylaxis of variceal bleeding in adults is the established standard of care because of the results of numerous randomised clinical trials demonstrating the efficacy of non-selective beta-blockers or endoscopic variceal ligation in decreasing the incidence of variceal bleeding. However, sclerotherapy is the only endoscopic prophylactic option currently available in infants weighing less than 10 kg of bodyweight due to the size of the endoscopic ligator.

Objectives: To assess the benefits and harms of sclerotherapy versus any type of beta-blocker for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.

Search methods: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, PubMed, Embase Elsevier, LILACS (Bireme), and Science Citation Index Expanded (Web of Science) in February 2019. We scrutinised the reference lists of the retrieved publications and performed a manual search from the main paediatric gastroenterology and hepatology conferences (NASPGHAN and ESPGHAN) abstract books from January 2008 to December 2018. We searched ClinicalTrials.gov, FDA, EMA, and WHO, for ongoing clinical trials. There were no language or document type restrictions.

Selection criteria: We planned to include randomised clinical trials irrespective of blinding, language, or publication status, assessing sclerotherapy versus any type of beta-blocker for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis. We planned to include quasi-randomised and other observational studies retrieved with the searches for randomised clinical trials for report of harm.

Data collection and analysis: We planned to collect and summarise data from randomised clinical trials as described in our protocol, using standard Cochrane methodologies.

Main results: We found no randomised clinical trials assessing sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.

Authors' conclusions: Randomised clinical trials assessing the benefits or harms of sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis are lacking. Therefore, trials with adequate power and proper design, assessing the benefits and harms of sclerotherapy versus beta-blockers on patient-relevant clinical outcomes such as mortality, failure to control bleeding, and adverse events are needed. Unless such trials are conducted and the results become published, we cannot make any conclusions regarding the benefits or harms of the two interventions.

PubMed Disclaimer

Conflict of interest statement

DG: none. LC: none. RTR: none. JCG: none.

Figures

1
1
Study flow diagram. Date of search: 28 February 2019.

Update of

  • doi: 10.1002/14651858.CD011659

References

References to studies excluded from this review

Andreani 1990 {published data only}
    1. Andreani T, Poupon RE, Balkau BJ, Trinchet JC, Grange JD, Peigney N, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (Baltimore, Md.) 1990;12(6):1413-9. [PMID: ] - PubMed

Additional references

Al‐Khazraji 2019
    1. Al-Khazraji A, Curry MP. The current knowledge about the therapeutic use of endoscopic sclerotherapy and endoscopic tissue adhesives in variceal bleeding. Expert Review of Gastroenterology & Hepatology 2019;13(9):893-7. [PMID: ] - PubMed
Angelico 2019
    1. Angelico R, Pietrobattista A, Candusso M, Tomarchio S, Pellicciaro M, Liccardo D, et al. Primary prophylaxis for gastrointestinal bleeding in children with biliary atresia and portal hypertension candidates for liver transplant: a single-center experience. Transplantation Proceedings 2019;51(1):171-8. [PMID: ] - PubMed
Bozic 2015
    1. Bozic MA, Puri K, Molleston JP. Screening and prophylaxis for varices in children with liver disease. Current Gastroenterology Reports 2015;17(7):27. - PubMed
Carneiro 2018
    1. Carneiro de Moura M, Chen S, Kamath BM, Ng VL, Ling SC. Acute Variceal Bleeding Causes Significant Morbidity. Journal of Pediatric Gastroenterology and Nutrition 2018;67(3):371-6. [PMID: ] - PubMed
Chan 2013
    1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical Research Ed.) 2013;346:e7586. [PMID: ] - PMC - PubMed
Chapin 2018
    1. Chapin CA, Bass LM. Cirrhosis and portal hypertension in the pediatric population. Clinics in Liver Disease 2018;22(4):735-52. [PMID: ] - PubMed
Cifuentes 2021a
    1. Cifuentes LI, Gattini D, Torres-Robles R, Gana JC. Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database of Systematic Reviews 2021, Issue 1. Art. No: CD011973. [DOI: 10.1002/14651858.CD011973.pub2] - DOI - PMC - PubMed
Cifuentes 2021b
    1. Cifuentes LI, Gattini D, Torres-Robles R, Gana JC. Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis. Cochrane Database of Systematic Reviews 2021, Issue 1. Art. No: CD011561. [DOI: 10.1002/14651858.CD011561.pub2] - DOI - PMC - PubMed
D'Amico 1999
    1. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Seminars in Liver Disease 1999;19(4):475-505. [PMID: ] - PubMed
Di Giorgio 2019
    1. Di Giorgio A, De Angelis P, Cheli M, Vajro P, Iorio R, Cananzi M, et al. Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: a multicentre national study. Digestive and Liver Disease 2019;51(8):1179-84. [PMID: ] - PubMed
Duche 2008
    1. Duche M, Habes D, Roulleau P, Haas V, Jacquemin E, Bernard O. Prophylactic endoscopic sclerotherapy of large esophagogastric varices in infants with biliary atresia. Gastrointestinal Endoscopy 2008;67(4):732-7. [PMID: ] - PubMed
Duche 2010
    1. Duche M, Ducot B, Tournay E, Fabre M, Cohen J, Jacquemin E, et al. Prognostic value of endoscopy in children with biliary atresia at risk for early development of varices and bleeding. Gastroenterology 2010;139(6):1952-60. [PMID: ] - PubMed
Duche 2013
    1. Duche M, Ducot B, Ackermann O, Baujard C, Chevret L, Frank-Soltysiak M, et al. Experience with endoscopic management of high-risk gastroesophageal varices, with and without bleeding, in children with biliary atresia. Gastroenterology 2013;145(4):801-7. [PMID: ] - PubMed
Duche 2017
    1. Duche M, Ducot B, Ackermann O, Guerin F, Jacquemin E, Bernard O. Portal hypertension in children: high-risk varices, primary prophylaxis and consequences of bleeding. Journal of Hepatology 2017;66(2):320-7. [PMID: ] - PubMed
Ebel 2019
    1. Ebel NH, Carlin K, Shaffer ML, Shivaram G, Hawkins M, Lane ER, et al. Hepatic venous pressure gradient measurements in children: correlation with hepatic histology and clinical indicators of portal hypertension. Journal of Pediatric Gastroenterology and Nutrition 2019;68(6):788-92. [PMID: ] - PMC - PubMed
El‐Karaksy 2015
    1. El-Karaksy HM, El-Koofy N, Mohsen N, Helmy H, Nabil N, El-Shabrawi M. Extrahepatic portal vein obstruction in Egyptian children. Journal of Pediatric Gastroenterology and Nutrition 2015;60(1):105-9. [PMID: ] - PubMed
Eroglu 2004
    1. Eroglu Y, Emerick KM, Whitingon PF, Alonso EM. Octreotide therapy for control of acute gastrointestinal bleeding in children. Journal of Pediatric Gastroenterology and Nutrition 2004;38(1):41-7. [PMID: ] - PubMed
Galand 2018
    1. Galand J, Ley D, Coopman S, Michaud L, Guimber D, Turck D, et al. Primary prophylaxis of oesophageal variceal bleeding in children by ligation is safe and as efficient as secondary prophylaxis. Journal of Hepatology 2018;68(3):600-1. [PMID: ] - PubMed
Gana 2010
    1. Gana JC, Turner D, Roberts EA, Ling SC. Derivation of a clinical prediction rule for the noninvasive diagnosis of varices in children. Journal of Pediatric Gastroenterology and Nutrition 2010;50(2):188-93. [PMID: ] - PubMed
Gana 2011a
    1. Gana JC, Valentino PL, Morinville V, O'Connor C, Ling SC. Variation in care for children with esophageal varices: a study of physicians', patients', and families' approaches and attitudes. Journal of Pediatric Gastroenterology and Nutrition 2011;52(6):751-5. [PMID: ] - PubMed
Gana 2011b
    1. Gana JC, Turner D, Mieli-Vergani G, Davenport M, Miloh T, Avitzur Y, et al. A clinical prediction rule and platelet count predict esophageal varices in children. Gastroenterology 2011;141(6):2009-16. [PMID: ] - PubMed
Gana 2019
    1. Gana JC, Cifuentes LI, Gattini D, Villarroel Del Pino LA, Pena A, Torres-Robles R. Band ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No: CD010546. [DOI: 10.1002/14651858.CD010546.pub2] - DOI - PMC - PubMed
Gana 2020
    1. Gana JC, Cifuentes LI, Gattini D, Torres-Robles R. Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No: CD011803. [DOI: 10.1002/14651858.CD011803.pub2] - DOI - PMC - PubMed
Garcia‐Tsao 2017
    1. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md.) 2017;65(1):310-35. [PMID: ] - PubMed
Gattini 2020
    1. Gattini D, Cifuentes LI, Torres-Robles R, Gana JC. Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No: CD011573. [DOI: 10.1002/14651858.CD011573.pub2] - DOI - PMC - PubMed
Goncalves 2000
    1. Goncalves ME, Cardoso SR, Maksoud JG. Prophylactic sclerotherapy in children with esophageal varices: long-term results of a controlled prospective randomized trial. Journal of Pediatric Surgery 2000;35(3):401-5. [PMID: ] - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 4 November 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.
Groszmann 2004
    1. Groszmann RJ, Bosch J, editor(s). Portal Hypertension in the 21st Century. Dordrecht: Kluwer Academic Publishers, 2004.
Hayes 1990
    1. Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990;336(8708):153-6. [PMID: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557-60. [PMID: ] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
ICH‐GCP 1997
    1. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1. Philadelphia (PA): Barnett International/PAREXEL, 1997.
Jeanniard‐Malet 2017
    1. Jeanniard-Malet O, Duche M, Fabre A. Survey on clinical practice of primary prophylaxis in portal hypertension in children. Journal of Pediatric Gastroenterology and Nutrition 2017;64(4):524-7. [PMID: ] - PubMed
Kamath 2001
    1. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology (Baltimore, Md.) 2001;33(2):464-70. [PMID: ] - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. - PubMed
Lampela 2012
    1. Lampela H, Kosola S, Koivusalo A, Lauronen J, Jalanko H, Rintala R, et al. Endoscopic surveillance and primary prophylaxis sclerotherapy of esophageal varices in biliary atresia. Journal of Pediatric Gastroenterology and Nutrition 2012;55(5):574-9. [PMID: ] - PubMed
Ling 2011
    1. Ling SC, Walters T, McKiernan PJ, Schwarz KB, Garcia-Tsao G, Shneider BL. Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research. Journal of Pediatric Gastroenterology and Nutrition 2011;52(3):254-61. [PMID: ] - PMC - PubMed
Lundh 2017
    1. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] - DOI - PMC - PubMed
Lykavieris 2000
    1. Lykavieris P, Gauthier F, Hadchouel P, Duche M, Bernard O. Risk of gastrointestinal bleeding during adolescence and early adulthood in children with portal vein obstruction. Journal of Pediatrics 2000;136(6):805-8. [PMID: ] - PubMed
McDiarmid 2002
    1. McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002;74(2):173-81. [PMID: ] - PubMed
Miga 2001
    1. Miga D, Sokol RJ, Mackenzie T, Narkewicz MR, Smith D, Karrer FM. Survival after first esophageal variceal hemorrhage in patients with biliary atresia. Journal of Pediatrics 2001;139(2):291-6. [PMID: ] - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352(9128):609-13. - PubMed
Ozsoylu 2000
    1. Ozsoylu S, Kocak N, Demir H, Yuce A, Gurakan F, Ozen H. Propranolol for primary and secondary prophylaxis of variceal bleeding in children with cirrhosis. Turkish Journal of Pediatrics 2000;42(1):31-3. [PMID: ] - PubMed
Parolini 2019
    1. Parolini F, Boroni G, Milianti S, Tonegatti L, Armellini A, Garcia Magne M, et al. Biliary atresia: 20-40-year follow-up with native liver in an Italian centre. Journal of Pediatric Surgery 2019;54(7):1440-4. [PMID: ] - PubMed
PCORI 2012
    1. Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PMID: ] - PubMed
Pimenta 2016
    1. Pimenta JR, Ferreira AR, Bittencourt PF, Resende CB, Fagundes ED, Silva IM. Evaluation of primary prophylaxis with propranolol and elastic band ligation in variceal bleeding in cirrhotic children and adolescents. Arquivos de Gastroenterologia 2016;53(4):257-61. [PMID: ] - PubMed
Pugh 1973
    1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery 1973;60(8):646-9. [PMID: ] - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603. - PubMed
Samanta 2011
    1. Samanta T, Purkait R, Sarkar M, Misra A, Ganguly S. Effectiveness of beta blockers in primary prophylaxis of variceal bleeding in children with portal hypertension. Tropical Gastroenterology 2011;32(4):299-303. [PMID: ] - PubMed
Savović 2012a
    1. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82. - PubMed
Savović 2012b
    1. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38. - PubMed
Savović 2018
    1. Savović J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JP, et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: the ROBES Meta-Epidemiologic Study. American Journal of Epidemiology 2018;187(5):1113-22. [PMID: ] - PMC - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. - PubMed
Shneider 2012
    1. Shneider BL, Bosch J, Franchis R, Emre SH, Groszmann RJ, Ling SC, et al. Portal hypertension in children: expert pediatric opinion on the report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatric Transplantation 2012;16(5):426-37. [PMID: ] - PubMed
Shneider 2016
    1. Shneider BL, Ville de Goyet J, Leung DH, Srivastava A, Ling SC, Duche M, et al. Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: summary of the Baveno VI Pediatric Satellite Symposium. Hepatology (Baltimore, Md.) 2016;63(4):1368-80. [PMID: ] - PubMed
Thorlund 2017
    1. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/wp-content/uploads/2020/12/tsa_manual_ENG.pdf 2017 (accessed 28 January 2021).
TSA 2017 [Computer program]
    1. Copenhagen Trial Unit TSA - Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. ctu.dk/tsa/downloads/.
van Heurn 2004
    1. Heurn LW, Saing H, Tam PK. Portoenterostomy for biliary atresia: long-term survival and prognosis after esophageal variceal bleeding. Journal of Pediatric Surgery 2004;39(1):6-9. [PMID: ] - PubMed
Verdaguer 2016
    1. Verdaguer DS, Gana AJ. Management of pediatric patients with esophageal varices [Enfrentamiento de pacientes pediatricos con varices esofagicas]. Revista Medica de Chile 2016;144(7):879-85. [PMID: ] - PubMed
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. - PubMed
Wetterslev 2009
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in a random‐effects meta-analysis. BMC Medical Research Methodology 2009;9:86. - PMC - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5. - PMC - PubMed

References to other published versions of this review

Gana 2015
    1. Gana JC, Cifuentes LI, Cerda J, Villarroel del Pino LA, Peña A, Torres-Robles R. Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No: CD011659. [DOI: 10.1002/14651858.CD011659] - DOI

Substances